Identifying Prognostic Factors in Elderly Patients with Amyloid Heart Disease
Identification of Prognostic Parameters in Patients With " Senile " Amyloid Cardiomyopathy
This study is trying to find out what factors affect the health of older patients with amyloid heart disease to help improve their treatment and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 142 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble Cedex 9) |
| Trial ID | NCT04225754 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify prognostic parameters in elderly patients diagnosed with cardiac amyloidosis, particularly focusing on those over 75 years old. It seeks to understand the relationship between senile amyloid cardiomyopathy and the increasing prevalence of heart failure with preserved ejection fraction (HFpEF) in older adults. The study will involve patients from four interventional cardiology centers in the Alpine region, where their cardiac health will be evaluated to better inform treatment strategies. By analyzing the pathophysiological aspects of coronary microcirculation, the study hopes to enhance the understanding of this condition and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are male or female patients over 75 years old diagnosed with cardiac amyloidosis.
Not a fit: Patients with concomitant ischemic cardiopathy or major non-cardiac illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and tailored treatment strategies for elderly patients with cardiac amyloidosis.
How similar studies have performed: While the specific focus on senile amyloid cardiomyopathy is less explored, similar studies on cardiac amyloidosis have shown promising results in understanding and treating the condition.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patient, over 75 years old * Social Security Affiliate * Any patient with the diagnosis of cardiac amyloidosis after etiological evaluation in one of the 4 Alpin arc interventional cardiology centers (Grenoble University Hospital, GHM Grenoble, Annecy Hospital and Chambéry Hospital). * Non opposition to participation Exclusion Criteria: * Concomitant ischemic cardiopathy with revascularization following cardiac scintigraphy exploration and subsequent coronary angiography. * Concomitant non-amyloid non-ischemic cardiopathy (valvular cardiopathy) * Major non-cardiac illness (eg, disseminated malignancy, severe neurological dysfunction at the time of diagnosis) or social condition that may preclude participation in a research study * Major patient protected by law (article L1121-8) * Person deprived of liberty (Article L1121-8)
Where this trial is running
Grenoble Cedex 9
- Chu Grenoble Alpes — Grenoble Cedex 9, France (Recruiting)
Study contacts
- Principal investigator: Charlotte CASSET — University Hospital, Grenoble
- Study coordinator: Charlotte Casset, Dr
- Email: ccasset@chu-grenoble.fr
- Phone: +33476763627
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.